Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity

J Thorac Cardiovasc Surg. 2016 Feb;151(2):444-50. doi: 10.1016/j.jtcvs.2015.10.003. Epub 2015 Oct 9.

Abstract

Background: Antithrombin is one of the main natural coagulation system inhibitors. It is potentiated by heparin, and may be a key component of heparin response, particularly in infants aged <1 year. We sought to determine the impact of baseline antithrombin activity on response to heparin and thrombin generation during cardiopulmonary bypass (CPB).

Methods: Secondary analysis was performed using linear regression analyses, which combined patients from a trial of individualized versus weight-based heparin management for 90 infants aged <1 year undergoing cardiac surgery.

Results: Mean baseline antithrombin activity was 0.69 ± 0.16 U/mL, and it was lower in neonates than in older infants (0.57 ± 0.15 vs 0.77 ± 0.12 U/mL; P < .001). Lower baseline antithrombin activity was associated with lower postheparin anti-Xa activity (EST [SE]: +0.47 (0.19) U/mL per 100 U/kg heparin; P = .01) and higher heparin doses during surgery (EST [SE]: +51 (17) U/kg per hour; P = .003). The administration of fresh frozen plasma attenuated the effect of low baseline antithrombin activity (interaction P value = .009). Patients with lower anti-Xa activity recorded during CPB had higher levels of thrombin-antithrombin complex (EST [SE]: +12.8 (4.7) ng/mL per -1 U/mL anti-Xa; P = .006); prothrombin activation fragment 1.2 (EST [SE]: +0.13 (0.07) log pg/mL per -1 U/mL anti-Xa; P = .06); and D-dimer (EST [SE]: -0.25 (0.09) log ng/mL per -1 U/mL anti-Xa; P = .009) in the postoperative period after adjustment for baseline antithrombin activity, duration of CPB, amount of fresh frozen plasma and heparin used throughout surgery in multivariable models.

Conclusions: Low circulating antithrombin activity is associated with lower heparin efficacy, which ultimately leads to a lower ability to suppress thrombin generation during CPB. Determination of risk factors for heparin resistance, and potentially, antithrombin replacement therapy, may individualize and improve anticoagulation treatment.

Keywords: antithrombin; congenital heart disease; heparin; surgery; thrombosis.

Publication types

  • Comparative Study

MeSH terms

  • Age Factors
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Antithrombin Proteins / metabolism*
  • Blood Coagulation / drug effects*
  • Blood Coagulation Tests
  • Blood Component Transfusion
  • Blood Loss, Surgical / prevention & control
  • Cardiac Surgical Procedures* / adverse effects
  • Cardiopulmonary Bypass* / adverse effects
  • Drug Resistance
  • Factor Xa / metabolism
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Heparin / administration & dosage*
  • Heparin / adverse effects
  • Humans
  • Infant
  • Infant, Newborn
  • Linear Models
  • Male
  • Multivariate Analysis
  • Peptide Fragments / blood
  • Plasma
  • Postoperative Hemorrhage / prevention & control
  • Prothrombin
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Thrombin / metabolism*
  • Treatment Outcome

Substances

  • Anticoagulants
  • Antithrombin Proteins
  • Fibrin Fibrinogen Degradation Products
  • Peptide Fragments
  • fibrin fragment D
  • prothrombin fragment 1.2
  • Prothrombin
  • Heparin
  • Thrombin
  • Factor Xa